A

AVECRIS

4 employees

AVECRIS is addressing one of gene therapy's most difficult challenges: long-lasting, cell-type-specific expression.

Basic info

Industry

biotechnology research

Sectors

Genetics
Life Science

Date founded

2022

Funding rounds raised

Total raised

$3.6M

from 1 investors over 1 rounds

A

AVECRIS raised $3.6M on January 1, 2022

Investors: Alameda Research

FAQ